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Objectives: Cyclin Decyclin-dependent kinase (CDK) 4/6einhibitor of CDK4/6eretinoblastoma (Rb)
pathway hyperactivation is associated with hormone receptor-positive (HRþ) breast cancer (BC). This
study assessed the biological activity of ribociclib (LEE011; CDK4/6 inhibitor) plus letrozole compared
with single-agent letrozole in the presurgical setting.
Materials and methods: Postmenopausal women (N ¼ 14) with resectable, HRþ, human epidermal
growth factor receptor 2-negative (HER2e) early BC were randomized 1:1:1 to receive 2.5 mg/day
letrozole alone (Arm 1), or with 400 or 600 mg/day ribociclib (Arm 2 or 3). Circulating tumor DNA and
tumor biopsies were collected at baseline and, following 14 days of treatment, prior to or during surgery.
The primary objective was to assess antiproliferative response per Ki67 levels in Arms 2 and 3 compared
with Arm 1. Additional assessments included safety, pharmacokinetics, and genetic proﬁling.
Results: Mean decreases in the Ki67-positive cell fraction from baseline were: Arm 169% (range 38e100%;
n ¼ 2), Arm 2 96% (range 78e100%; n ¼ 6), Arm 3 92% (range 75e100%; n ¼ 3). Decreased phosphorylated
Rb levels and CDK4, CDK6, CCND2, CCND3, and CCNE1 gene expression were observed following ribociclib
treatment. Ribociclib and letrozole pharmacokinetic parameters were consistent with single-agent data.
The ribociclib plus letrozole combination was well tolerated, with no Grade 3/4 adverse events over the
treatment.
Conclusion: The results suggest absence of a drugedrug interaction between ribociclib and letrozole and
indicate ribociclib plus letrozole may reduce Ki67 expression in HRþ, HER2e BC (NCT01919229).
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).: þ39 02 94379224.
igliano).
Ltd. This is an open access article uIntroduction
Endocrine therapy is a key treatment strategy for hormone
receptor-positive (HRþ) breast cancer due to the dependency of
these tumors on estrogen signaling [1]. Combining endocrinender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
G. Curigliano et al. / The Breast 28 (2016) 191e198192therapy with targeted therapies may enhance the effect of treat-
ment by targeting compensatory pathways that act downstream of
estrogen signaling. Short-term, window-of-opportunity studies of
drug combinations can inform the optimal biological dose [2],
enable the investigation of pharmacodynamic (PD) markers, iden-
tify biomarkers for patient selection, and may expedite drug
development [3]. Moreover, short-term endpoints in window-of-
opportunity studies, such as cell proliferation as measured by
Ki67, can act as surrogate markers of longer-term patient outcomes
[4], and several short-term studies have contributed to treatment
decisions for endocrine therapy, including the potential of combi-
nation therapies [5] and the preferred patient biomarker proﬁle [6].
The cyclin Decyclin-dependent kinase (CDK) 4/6einhibitor of
CDK4/6 (INK4)eretinoblastoma (Rb) pathway acts downstream of
estrogen receptor (ER) activation to promote cell cycle progression
and cell division in response to estrogen signaling [7]. As such,
endocrine therapy inhibits activation of this pathway, down-
regulating cell proliferation [8]. Recent data demonstrate that
endocrine therapy-resistant tumor cells are able to maintain cyclin
DeCDK4/6eINK4eRb pathway activity [1]. Additionally, the cyclin
DeCDK4/6eINK4eRb pathway is frequently disrupted in favor of
cell cycle progression in HRþ breast cancer [9e11] and has been
associated with poor clinical outcome [1]. Therefore, targeting the
cyclin DeCDK4/6eINK4eRb pathway may present an effective
strategy to enhance the efﬁcacy of endocrine therapies.
Ribociclib (LEE011) is an orally bioavailable, selective inhibitor of
CDK4/6 that prevents Rb phosphorylation, resulting in G1 cell cycle
arrest in vitro [12,13]. Ribociclib has exhibited synergistic activity
with letrozole in preclinical xenograft models of ER-positive (ERþ)
breast cancer [14]. In clinical trials, ribociclib has demonstrated
clinical activity both as a single agent in patients with advanced
solid tumors, and when administered in combination with letro-
zole to patients with advanced ERþ, human epidermal growth
factor receptor 2-negative (HER2e) breast cancer [15,16].
We report results of a Phase II, window-of-opportunity, pre-
surgical treatment study evaluating the safety, pharmacokinetics
(PK), and PD of two clinical doses of ribociclib (400mg and 600mg)
in combination with letrozole versus single-agent letrozole in HRþ
early breast cancer (ClinicalTrials.gov study number:
NCT01919229).
Material and methods
Study design
The primary objective of this multicenter, randomized study
(Fig. 1) was to assess the difference in antiproliferative activity of
ribociclib in combination with letrozole versus single-agent letro-
zole, as measured by changes in expression level of the proliferative
marker Ki67 from baseline to time of surgery. Secondary objectives
included the assessment of safety, tolerability, and PK of ribociclib
and letrozole in combination, and the evaluation of PD markers
related to ribociclib activity in breast cancer. The study also evalu-
ated potential correlations between ribociclib exposure and major
safety and biomarker parameters, changes in biomarkers related to
the cyclin DeCDK4/6eINK4eRb pathway, and the role of circulating
tumor DNA (ctDNA) as a potential platform for molecular charac-
terization. Patients were treated with once-daily letrozole 2.5 mg
(Arm 1), with or without once-daily ribociclib 400 mg (Arm 2) or
600 mg (Arm 3) for 14 days (±3 days) prior to surgery.
Patient population
Adult postmenopausal women with treatment-naïve, newly
diagnosed, surgically resectable, Grade II/III HRþ, HER2e invasivebreast cancer were included in this study. Patients were required to
have at least one breast lesion with a diameter of 1.0 cm
conﬁrmed by ultrasound, mammography, computed tomography,
or magnetic resonance imaging. All patients had an Eastern Coop-
erative Oncology Group performance status of 0 or 1 and adequate
bone marrow and organ function. Patients were excluded based on
the presence of a concurrent malignancy or a history of malignancy
within 3 years of randomization, with the exception of adequately
treated basal cell skin cancer, squamous cell carcinoma, non-
melanomatous skin cancer, or curatively resected cervical cancer.
Key exclusion criteria also included active cardiac disease or a
history of cardiac dysfunction, including having a left ventricular
ejection fraction of <50% as determined by a multiple-gated
acquisition scan or an echocardiogram, and a QT corrected using
Fridericia's formula (QTcF) of >450 ms. Patients were excluded if
they were receiving medications that are known strong inducers or
inhibitors of cytochrome P450 3A4 (CYP3A4), have a narrow ther-
apeutic window and are predominantly metabolized through
CYP3A4, or have a known risk of prolonging the QT interval or
inducing Torsades de Pointes.
Safety assessments
Safety assessments were conducted at baseline and at scheduled
intervals throughout the study. Hematology, blood chemistry,
thyroid function, vital signs, and physical condition were regularly
monitored. Cardiac function was monitored by performing tripli-
cate electrocardiograms (ECGs) within 72 h prior to randomization
and again on Days 1, 8, and 14 at the following time points: pre-
dose and 2, 4, and 6 h after treatment dose. In each case, the ECG
measurements were collected prior to PK sampling. In addition,
patients were ﬁtted with a Mortara H12þ Holter (Mortara Instru-
ment, Milwaukee,WI, USA) instrument to carry out continuous ECG
recordings over a 24-h period both at baseline (within 1 day prior to
the ﬁrst dose) and on Day 14 approximately 24 h prior to surgery.
Adverse events (AEs) were assessed continuously according to the
Common Terminology Criteria for Adverse Events version 4.03.
Pharmacokinetic assessments
Blood samples for the analysis of ribociclib and letrozole plasma
concentrations were collected on Days 1, 8, and 14 at pre-dose and
2, 4, and 6 h after treatment dose. An additional PK blood sample
was collected on Day 15 approximately 24 h after the last treatment
dose on Day 14 and immediately prior to surgery. Plasma concen-
trations were measured using validated liquid chromatogra-
phyetandem mass spectrometry with a lower limit of
quantiﬁcation (LLOQ) of approximately 1.0 ng/mL for ribociclib and
2.0 ng/mL for letrozole. PK parameters were derived from indi-
vidual plasma concentrationetime proﬁles using non-
compartmental analysis (Phoenix®; Pharsight, Mountain View,
CA, USA) and were summarized using descriptive statistics.
Pharmacodynamic and biomarker assessments
Both tumor tissue samples and plasma samples for ctDNA were
collected at baselineprior to theﬁrst doseof treatment andonDay15
(±3 days) at, or immediately prior to, surgery. Blood samples for
estradiol assessment were collected prior to the ﬁrst dose of study
treatment and prior to surgery on Day 14 (±3 days). Immunohisto-
chemistry (IHC) detection of Ki67-positive tumor cells was per-
formed on baseline and surgery tumor tissue samples to assess
changes in the percentage of positive tumor cells. To assess the PD
activityof ribociclib, changes inS780-phosphorylatedRb (pRb) levels
in tumor samples were evaluated by IHC with H-score values
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Fig. 1. Study design. Abbreviations: D: day; HER2e: human epidermal growth factor receptor 2-negative; HRþ: hormone receptor-positive; NGS: next-generation sequencing;
PK: pharmacokinetics; pRb: phosphorylated retinoblastoma. Tumor biopsy and blood samples were collected during treatment on the indicated days for the assessment of Ki67
expression, pRb level, and estradiol concentration, and for NGS and PK analysis.
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estradiol serum concentrations were evaluated using an enzyme-
linked immunosorbent assay. Paired tumor tissue samples were
used to analyze the expression of genes involved in the cyclin
DeCDK4/6eINK4eRbpathway usingNanoString® technology. Next-
generation sequencing (NGS) of all ctDNA and tumor tissue samples
was performed using a 542-gene targeted panel to assess potential
molecular alterations in genes associated with ERþ breast cancer.
Results
Patient characteristics and disposition
Table 1 summarizes the characteristics of all patients enrolled in
the study. From October 10, 2013 to July 17, 2014, 14 patients with a
median age of 65 years (range 51e78 years) were randomized to
one of three treatment arms: letrozole 2.5 mg/day (Arm 1, n ¼ 4),
letrozole 2.5 mg/day plus ribociclib 400 mg/day (Arm 2, n ¼ 6) or
600 mg/day (Arm 3, n ¼ 4). Thirteen patients (93%) completed
treatment; one patient in Arm 3 discontinued due to patient de-
cision. This study was prematurely terminated on July 17, 2014, due
to low patient enrollment.Table 1
Patient characteristics.
Characteristic Arm 1: Letrozole 2.5 mg/day
(n ¼ 4)
Arm 2: Ribocicli
letrozole 2.5 mg
Age, years, median (range) 57 (51e63) 65 (51e78)
Age, n (%)
<65 years 4 (100) 3 (50)
65 years 0 3 (50)
Race, n (%)
Caucasian 4 (100) 6 (100)
Ethnicity, n (%)
Hispanic 1 (25) 0
Not reported 3 (75) 0
Other 0 5 (83)
Unknown 0 1 (17)
BMI, kg/m2, median (range) 28 (21e36) 29 (27e43)
ECOG PS, n (%)
0 4 (100) 4 (67)
1 0 2 (33)
Abbreviations: BMI: body mass index; ECOG: Eastern Cooperative Oncology Group; PS:Safety and tolerability
All AEs suspected to be related to study treatment were mild or
moderate in severity with no associated Grade 3/4 AEs. AEs of any
grade suspected to be study drug-related occurred in 25% of pa-
tients in Arm 1 (1/4), 50% of patients in Arm 2 (3/6), and 100% of
patients in Arm 3 (4/4). Two AEs suspected to be related to study
treatment occurred in Arm 1: nausea and hypomagnesemia (n ¼ 1
each; both Grade 1/2; Table 2). The most frequent treatment-
related AEs (n > 1) in Arms 2 or 3 were nausea, asthenia, QTcF
prolongation, and decreased appetite (n ¼ 2 each; all Grade 1/2).
One patient in Arm 3 experienced an asymptomatic increase in
QTcF from baseline of >60 mse490 ms. Six patients had QTcF
changes of >30 ms (Arm 1, n ¼ 2; Arm 2, n ¼ 1; Arm 3, n ¼ 3).
Pharmacokinetics
Following oral dosing, both ribociclib and letrozole were rapidly
absorbed, with maximum plasma concentration (Cmax) achieved
between 2 and 4 h and 2 h, respectively, after both single (Day 1)
and multiple (Day 8 and Day 14) doses (Table 3). The plasma con-
centration of ribociclib increased two- to three-fold from Day 1 tob 400 mg/day þ
/day (n ¼ 6)
Arm 3: Ribociclib 600 mg/day þ
letrozole 2.5 mg/day (n ¼ 4)
All patients (N ¼ 14)
70 (66e75) 65 (51e78)
0 7 (50)
4 (100) 7 (50)
4 (100) 14 (100)
0 1 (7)
0 3 (21)
3 (75) 8 (57)
1 (25) 2 (14)
26 (25e34) 29 (21e43)
3 (75) 11 (79)
1 (25) 3 (21)
performance status.
Table 2
All-grade adverse events suspected to be study treatment-related (15% in any treatment arm).
Adverse event,
n (%)
Arm 1: Letrozole 2.5 mg/day (n ¼ 4) Arm 2: Ribociclib 400 mg/day þ
letrozole 2.5 mg/day (n ¼ 6)
Arm 3: Ribociclib 600 mg/day þ
letrozole 2.5 mg/day (n ¼ 4)
Total 1 (25) 3 (50) 4 (100)
Abdominal pain 0 0 1 (25)
Diarrhea 0 0 1 (25)
Nausea 1 (25) 0 2 (50)
Stomatitis 0 1 (17) 0
Vomiting 0 0 1 (25)
Asthenia 0 1 (17) 1 (25)
Fatigue 0 0 1 (25)
QTcF prolongation 0 0 2 (50)
Decreased appetite 0 0 2 (50)
Hypomagnesemia 1 (25) 0 0
Dyspnea 0 1 (17) 0
Hot ﬂush 0 0 1 (25)
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z30 h [17], with steady-state reached by approximately Day 8.
Ribociclib exposure increased with increasing doses from 400 mg/
day to 600 mg/day in a slightly greater than proportional manner
(Table 3). Letrozole PK parameters (Cmax, time to maximum plasma
concentration, and area under the concentrationetime curve) were
comparable across all treatment arms (Table 3). The plasma con-
centration of letrozole increased between four- and ﬁve-fold from
Day 1 to Day 14.
Pharmacodynamic analyses
Ki67 levels were decreased following study treatment in all
11 evaluable patients with matched baseline and posttreatment
tumor samples (Fig. 2). Treatment with single-agent letrozole
resulted in a mean decrease in Ki67-expressing cells of 69% (range
38e100%; n ¼ 2). The mean percent decrease in Arm 2 (400 mg
ribociclib) was 96% (range 78e100%; n ¼ 6) and in Arm 3 (600 mg
ribociclib) was 92% (range 75e100%; n ¼ 3).
Ribociclib PD activity was assessed in tumor samples according
to the change in pRb level and any alterations in the expression of
cyclin DeCDK4/6eINK4-Rb pathway genes from baseline to Day 15.
Baseline levels of pRb varied between patient samples, and both
increased and decreased pRb levels from baseline to Day 15 wereTable 3
Primary ribociclib and letrozole pharmacokinetic parameters.
Treatment Analyte Day n Cmax (
Arm 1:
Letrozole 2.5 mg/day (n ¼ 4)
Letrozole 1 4 21 (
8 4 68 (
14 3 86 (
Arm 2:
Ribociclib 400 mg/day þ letrozole
2.5 mg/day (n ¼ 6)
Ribociclib 1 5 350 (
8 5 906 (
14 6 1022 (
Letrozole 1 6 16 (
8 5 66 (
14 6 83 (
Arm 2:
Ribociclib 600 mg/day þ letrozole
2.5 mg/day (n ¼ 4)
Ribociclib 1 3 1168 (
8 3 2610 (
14 3 3083 (
Letrozole 1 3 19 (
8 3 65 (
14 2 88 (
Abbreviations: AUC: area under the concentrationetime curve; Cmax: maximum p
concentration.
a Mean (SD).
b Median (range).
c n ¼ 3.
d n ¼ 5.
e n ¼ 2.observed across the three treatment arms. The variation observed
between patients in each group, together with the small number of
evaluable paired samples (n ¼ 10) precludes a deﬁnitive conclusion
regarding the impact of ribociclib on pRb levels. In Arm 1 (single-
agent letrozole), pRb levels increased from baseline to Day 15 in
both evaluable patients, while pRb levels decreased in ﬁve out of
eight evaluable patients in Arms 2 and 3 (Arm 2, n ¼ 4/6; Arm 3,
n ¼ 1/2); the mean percent decrease in pRb levels was 59% (range
31e95%; n ¼ 5).
Analysis of cyclinDeCDK4/6eINK4eRbpathwaygene expression
in tumor tissue revealed that across 10 evaluable samples, theremay
be a trend for decreased expression of cyclin DeCDK4/6eINK4eRb
pathway-related genes, such as CDK4 and CDK6, upon ribociclib
treatment compared with letrozole treatment alone (Fig. 3). Due to
the small number of evaluable patient samples in each group (Arm1,
n¼ 2; Arm 2, n¼ 6; Arm 3, n¼ 2), no conclusions can be made as to
any potential dose effect of ribociclib.
The PD activity of letrozole was evaluated according to the
change in plasma estradiol levels from baseline to Day 14 in seven
evaluable paired tumor samples. Posttreatment estradiol levels
were decreased 100% below the LLOQ (0.5 pg/mL) for six of the
seven evaluable patients. One patient in Arm 2 had an observed
increase in estradiol levels of 243% that was most likely the result of
perimenopausal changes (age 51 years).ng/mL)a Tmax (h)b AUC0e6h (ngh/mL)a AUC0e24h (ngh/mL)a
8) 2 (2e4) 76 (23) e
28) 2 (2e3) 352 (143)c e
35) 2 (2e2) 460 (200) 1684 (773)
122) 4 (2e4) 1391 (395) e
419) 4 (2e6) 4338 (2183) e
527) 3 (2e6) 4867 (2633) 15,482 (8629)d
2) 2 (2e5) 62 (8)d e
13) 2 (2e6) 335 (61) e
14) 2 (2e6) 450 (78) 1692 (459)d
513) 2 (2e4) 4714 (1607) e
547) 4 (2e4) 11,173 (1830) e
966) 2 (2e2) 13,348 (5461)e 38,896 (16,826)e
7) 2 (2e2) 89 (30) e
14) 2 (2e2) 333 (93) e
9) 2 (2e2) 462 (2) 1577 (90)
lasma concentration; SD: standard deviation; Tmax: time to maximum plasma
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NGS analysis was performed on both tumor tissue and plasma
ctDNA samples collected from 12 patients, while one patient had
only ctDNA samples available for NGS analysis. Tumor sample
analysis of over 500 genes identiﬁed alterations in commonly re-
ported breast cancer-related genes such as ARID1A, CDH1, GATA3,
PIK3CA, and TP53 [10,18] (Fig. 4A). None of the patients had a mu-
tation in the Rb gene (RB1). Compared with the results of the tumor
sample analysis, alterations were detected in plasma ctDNA sam-
ples much less frequently. Plasma ctDNA allelic fractions showed
little variation between samples collected at screening and those
collected at Day 15 (Fig. 4B).
Discussion
In this window-of-opportunity study, patients with HRþ,
HER2e early breast cancer received letrozole with or withoutribociclib prior to surgery. There were few enrolled patients in each
treatment group with evaluable samples, precluding deﬁnitive
conclusions regarding PK, PD, and biomarker evaluations. Accrual
may have been affected by the short duration of therapy, which
may have a limited clinical beneﬁt, coupled with the clinical
complexity of this window-of-opportunity study (multiple assess-
ments and extensive cardiac monitoring). Other factors that may
have affected accrual include ineligibility due to limited tissue
availability, HR status, or lesion size. Overall, the combination of
ribociclib and letrozole was well tolerated, with no Grade 3/4 AEs
reported over a 2-week treatment period. The PK proﬁle of ribo-
ciclib in the presence of letrozole was consistent with historical
single-agent ribociclib data [19], indicating that ribociclib PK is not
substantially affected by letrozole. The direct comparison of letro-
zole PK parameters across the three treatment arms indicates that
there is no signiﬁcant effect of ribociclib on letrozole PK.
The extent to which letrozole, with or without ribociclib,
inhibited cell proliferation was measured according to Ki67 levels.
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good predictive marker of the outcome of treatment in larger trials
[20], making Ki67 a valuable PD marker of the effectiveness of
medical therapy [21]. All patients in this trial experienced a
decrease from baseline in the percentage of cells expressing the
Ki67 proliferation marker following treatment with either single-
agent letrozole or letrozole in combination with ribociclib. These
results are in agreement with the known role of ribociclib as a cell
cycle inhibitor [12,13] and consistent with the observed reduction
in Ki67 levels following treatment with a CDK4/6 inhibitor in
combination with anastrozole [22]. Recent clinical trial data
demonstrate the clinical beneﬁt of ribociclib in combination with
endocrine therapy, including exemestane [23] and letrozole [16], in
patients with ERþ, HER2e breast cancer. Additionally, co-
administration of a CDK4/6 inhibitor with either letrozole [24] or
fulvestrant [25] signiﬁcantly prolonged the progression-free sur-
vival of postmenopausal women with HRþ, HER2e advanced
breast cancer.
Signs of cyclin DeCDK4/6eINK4eRb pathway inhibition were
also observed with ribociclib treatment. Decreased pRb levels were
observed in ﬁve out of eight evaluable patients treated with ribo-
ciclib. The lack of a decrease in pRb levels following ribociclib
treatment in some patient samples could be explained by potential
activity of ribociclib on phosphorylation sites other than S780,
which were not assessed in this study. Rb contains 13 sites for CDK
phosphorylation [26], yet the number and combination of sites
required for cell cycle control remains unknown [27]; thus a lack of
S780 dephosphorylationmay not directly correlate with Rb activity.
Additionally, although IHC is a critical component of tumor char-
acterization, there is a degree of inherent subjectivity and vari-
ability [28]. The small sample size in this study, combined with
variability and inherent issues of IHC quantitation, means the re-
sults cannot be clearly interpreted. On-target inhibition of the
cyclin DeCDK4/6eINK4-Rb pathway was also suggested by the
analysis of cyclin DeCDK4/6eINK4eRb pathway gene expression.
Recent studies have suggested the potential of using ctDNA
analysis as a less invasive method of tumor molecular character-
ization [29] and to inform prognosis in early-stage and metastatic
breast cancer [30]. Studies have demonstrated the ability of
ctDNA proﬁling to detect mutations in target genes [31,32].
However, in line with other reports [29,33] this study highlights
the potential challenges in utilizing ctDNA in the context of newly
diagnosed breast cancer with low levels of tumor DNA in the
circulation. Detection levels of ctDNA are >50% in the case of non-
metastatic breast cancer compared with >75% in metastatic breast
cancer [29] and have been reported as low as 24% in some cases
[33]. Technical advancements that improve the sensitivity and
speciﬁcity of ctDNA analysis should enable ctDNA analysis to
detect and characterize early disease states [34]. In this study, few
genetic alterations were detected in ctDNA samples in compari-
son with tumor samples. Analysis of ctDNA samples showed
robustness across time points, with concordance in allelic frac-
tions between baseline and Day 15. However, further studies of
concordance are needed in patients with higher levels of tumor
DNA in the circulation.
Conclusions
Collectively, the ﬁndings from this study indicated that the
combination of ribociclib and letrozole was associated with an
acceptable safety proﬁle over a 2-week treatment period. The
comparison of letrozole PK parameters across all treatment arms
suggests the absence of a drugedrug interaction between ribociclib
and letrozole. The ability of ribociclib in combinationwith letrozole
to improve progression-free survival compared with letrozolesingle-agent has recently been conﬁrmed in the Phase III
MONALEESA-2 trial [35] in postmenopausal patients with HRþ,
HER2e advanced breast cancer (ClinicalTrials.gov study number:
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